Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi

suck pdf from helios

10.1111/ajt.15943

http://scihub22266oqcxt.onion/10.1111/ajt.15943
suck pdf from google scholar
32337790!7267503!32337790
unlimited free pdf from europmc32337790    free
PDF from PMC    free
html from PMC    free
PDF vom PMID32337790  :  Publisher
PDF vom PMID32337790

suck abstract from ncbi

pmid32337790
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Severe COVID-19 in a renal transplant recipient: A focus on pharmacokinetics #MMPMID32337790
  • Meziyerh S; Zwart TC; van Etten RW; Janson JA; van Gelder T; Alwayn IPJ; de Fijter JW; Reinders MEJ; Moes DJAR; de Vries APJ
  • Am J Transplant 2020[Jul]; 20 (7): 1896-1901 PMID32337790show ga
  • The current coronavirus disease 2019 (COVID-19) pandemic requires extra attention for immunocompromised patients, including solid organ transplant recipients. We report on a case of a 35-year-old renal transplant recipient who suffered from a severe COVID-19 pneumonia. The clinical course was complicated by extreme overexposure to the mammalian target of rapamycin inhibitor everolimus, following coadministration of chloroquine and lopinavir/ritonavir therapy. The case is illustrative for dilemmas that transplant professionals may face in the absence of evidence-based COVID-19 therapy and concurrent pressure for exploration of experimental pharmacological treatment options. However, the risk-benefit balance of experimental or off-label therapy may be weighed differently in organ transplant recipients than in otherwise healthy COVID-19 patients, owing to their immunocompromised status and potential drug interactions with immunosuppressive therapy. With this case report, we aimed to achieve increased awareness and improved management of drug-drug interactions associated with the various treatment options for COVID-19 in renal transplant patients.
  • |*Kidney Transplantation[MESH]
  • |*Transplant Recipients[MESH]
  • |Adult[MESH]
  • |Antiviral Agents/administration & dosage/pharmacokinetics[MESH]
  • |Betacoronavirus[MESH]
  • |COVID-19[MESH]
  • |Chloroquine/administration & dosage/pharmacokinetics[MESH]
  • |Coronavirus Infections/*complications/*therapy[MESH]
  • |Drug Combinations[MESH]
  • |Drug Interactions[MESH]
  • |Everolimus/administration & dosage/*pharmacokinetics[MESH]
  • |Humans[MESH]
  • |Immunocompromised Host[MESH]
  • |Immunosuppressive Agents/administration & dosage/pharmacokinetics[MESH]
  • |Kidney Failure, Chronic/*complications/surgery[MESH]
  • |Lopinavir/administration & dosage/pharmacokinetics[MESH]
  • |Male[MESH]
  • |Netherlands[MESH]
  • |Pandemics[MESH]
  • |Pneumonia, Viral/*complications/*therapy[MESH]
  • |Radiography, Thoracic[MESH]
  • |Ritonavir/administration & dosage/pharmacokinetics[MESH]
  • |SARS-CoV-2[MESH]
  • |Treatment Outcome[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    1896 7.20 2020